Charles River Laboratories International, Inc. (CRL) News
Latest headlines that mention CRL, newest first · each headline opens the original publisher
- Last price
- $339.66
- Day change
- -1.51%
- Next earnings
- 2026-11-04 BMO
CRL headlines
latest coverageOrganic revenue returned to growth as biopharmaceutical demand strengthened.
Shares of Charles River Laboratories blew out of a buy zone Wednesday after the medtech company hit its highest book-to-bill ratio in four years. The post Charles River Blows Out Of A Buy Zone After One Metric Hits A Four-Year High appeared first on Investor's Business Daily .
Wall Street just split sharply on two stocks in the same industry. On Wednesday, June 17, Morgan Stanley upgraded Charles River Laboratories (CRL) to Overweight and downgraded IQVIA Holdings (IQV) to Equal-weight. The twist: IQVIA is buying lab assets that Charles River agreed…
CRL news alerts
Get an alert by email or push when a new headline mentions CRL.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.